COMBINING PI3K, CDK4/6 PATHWAY INHIBITORS AND CHECKPOINT BLOCKADE IN TRIPLE-NEGATIVE BREAST CANCER

Grant number: 1123208 | Funding period: 2017 - 2019

Completed

Abstract

Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.